Selcan Demir
Selcan is a pediatric rheumatologist at Eskisehir Osmangazi University. Her major interests include juvenile SLE and APS. Selcan is a member of EMERGE and leading the clinical affair committee of the PRES SLE working party.
| Type, n° | Date, time | Session | Author | Title |
|---|---|---|---|---|
| Oral 0163 | Thursday, 01.06.2023 11:05 – 11:15 | New Insights in the care and management of JIA | Zimmer, A (Germany) | GOLIMUMAB FOR THE TREATMENT OF POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS – AN UPDATE ON SAFETY AND EFFECTIVENESS FROM THE BIKER REGISTRY |
| This study showed that Golimumab is effective and has an acceptable safety profile in the treatment of pJIA. | ||||
| Poster 0133 | Friday, 02.06.2023 12:05 – 12:10 | What’s new in Paediatric RMDs? | Bracaglia, C (Italy) | TRADITIONAL LABORATORY PARAMETERS AND NEW BIOMARKERS IN MACROPHAGE ACTIVATION SYNDROME (MAS) AND SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (sHLH) |
| This study evaluated the diagnostic and prognostic role of IL-18, CXCL9, CXCL10, and neopterin in patients with MAS and sHLH. | ||||
| Poster 0134 | Friday, 02.06.2023 12:10 – 12:15 | What’s new in Paediatric RMDs? | Bergkamp, S (Netherlands) | LEARNING FROM LONGITUDINAL DATA IN CHILDHOOD ONSET SYSTEMIC LUPUS ERYTHEMATOSUS: WHICH BIOMARKERS HAVE PREDICTIVE VALUE FOR ENDOTHELIAL INVOLVEMENT? |
| This study suggested some predictive biomarkers for endothelial cell activation and a pro-angiogenic state in juvenile SLE. | ||||
| Poster 0287 | Saturday, 03.06.2023 10:50 – 10:55 | Advances in our care of children and young people with JIA) | Horneff, G (Germany) | TOFACITINIB IN JUVENILE IDIOPATHIC ARTHRITIS: FIRST YEAR EXPERIENCE |
| This preliminary analysis of paediatric patients with JIA showed that tofacitinib use is safe and well tolerated. | ||||
| Poster 0279 | Saturday, 03.06.2023 10:10 – 10:15 | Poster tour: Advances in our care of children and young people with JIA | Bracaglia, C (Italy) | IDENTIFICATION OF PREDICTIVE FACTORS OF FLARE AFTER ANAKINRA WITHDRAWAL IN PATIENTS WITH SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS: RESULTS FROM A SINGLE CENTRE |
| This study supported “window of opportunity” hypothesis which means that early anakinra treatment may prevent the development of a persistent disease course. | ||||
| Oral 0300 | Saturday, 03.06.2023 10:05 – 10:15 | Treating to Target: Challenges across the life course | Van Dijk, B (Netherlands) | INCREASING THE ETANERCEPT DOSE IN JUVENILE IDIOPATHIC ARTHRITIS PATIENTS: DOES IT HELP REACHING THE TREATMENT TARGET? A POST-HOC ANALYSIS OF THE BEST4KIDS RANDOMISED CLINICAL TRIAL |
| This single blinded treatment strategy trial do not indicate superior clinical outcomes after etanercept dose increase, but there is a potential trend for more infectious AEs. | ||||